Compare CLST & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | XBIT |
|---|---|---|
| Founded | 1922 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 74.4M |
| IPO Year | 2021 | 2015 |
| Metric | CLST | XBIT |
|---|---|---|
| Price | $15.95 | $2.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.8K | ★ 27.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $106.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.02 | $2.09 |
| 52 Week High | $18.16 | $3.61 |
| Indicator | CLST | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 39.06 |
| Support Level | $15.90 | $2.26 |
| Resistance Level | $15.99 | $2.69 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 62.46 | 10.34 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.